Dr. Cath Mummery and Jessica Langbaum Report Experimental Drug Diranersen Slows Alzheimer’s Decline By Targeting Tau Protein
An experimental drug, diranersen, has shown promising signs of slowing cognitive decline in early Alzheimer’s disease by reducing levels of tau protein, according to recent study results. Researchers noted that the drug targets tau, a different aspect of the disease than currently approved therapies focusing on amyloid buildup. During the study, Dr. Cath Mummery, who led the research, reported that recipients experienced a slower rate of memory decline, a finding comparable to that seen with existing treatments. Jessica Langbaum remarked that the results are promising for future development. While caution remains, the data suggests that lowering tau production could enhance the brain's natural clearance mechanisms. The findings, presented by Biogen, aim to advance treatment options beyond current anti-amyloid drugs. The research supports ongoing scientific efforts to find treatments that can more effectively penetrate the brain. Experts emphasize that further, larger studies are necessary before any conclusions can be drawn regarding clinical use.